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Background: Symptoms of COPD are frequently disregarded by patients and also by general practitioners (GPs)
in early stages of the disease, that consequently is diagnosed when already at an advanced grade of severity.
Underdiagnosis and undertreatment of COPD and scarce use of spirometry are widely recurrent, while a better
knowledge of the disease and a wider use of spirometry would be critical to diagnose more patients still
neglected, do it at an earlier stage and properly treat established COPD. The aim of Pneumocafè project is to
improve, through an innovative approach, the diagnosis and management of COPD at primary care level
increasing the awareness of issues pertaining to early diagnosis, adequate prevention and correct treatment of
the disease.
Methods: Pneumocafè is based on informal meetings between GPs of various geographical zones of Italy and
their reference respiratory specialist (RS), aimed at discussing the current practice in comparison to suggestions
of official guidelines, analyzing the actual problems in diagnosing and managing COPD patients and sharing the
possible solution at the community level. In these meetings RSs faced many issues including patho-physiological
mechanisms of bronchial obstruction, significance of clinical symptoms, patients’ phenotyping, and clinical approach to
diagnosis and long-term treatment, also reinforcing the importance of a timely diagnosis, proper long term treatment
and the compliance to treatment. At the end of each meeting GPs had to fill in a questionnaire arranged by the
scientific board of the Project that included 18 multiple-choice questions concerning their approach to COPD
management. The results of the analysis of these questionnaires are here presented.
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Results: 1, 964 questionnaires were returned from 49 RSs. 1,864 questionnaires out of those received (94.91% of the
total) resulted properly compiled and form the object of the present analysis. The 49 RSs, 37 males and 12 females,
were distributed all over the Italian country and practiced their profession both in public and private hospitals
and in territorial sanitary facilities. GPs were 1,330 males (71.35%) and 534 females (28.64%), mean age
56,29 years (range 27-70 yrs). Mean duration of general practice was 25.56 years (range: 0,5-40 yrs) with a mean
of 1,302.43 patients assisted by each GP and 2,427,741 patients assisted in all. The majority of GPs affirmed that
in their patients COPD has a mean-to-great prevalence and a mean/high impact on their practice, preceded only
by diabetes and heart failure. Three-quarters of GPs refer to COPD guidelines and most of them believe that a
screening on their assisted patients at risk would enhance early diagnosis of COPD. Tobacco smoking is the main
recognized cause of COPD but the actions carried out by GPs to help a patient to give up smoking result still insufficient.
The majority of GPs recognize spirometry as necessary to early COPD diagnosis, but the main obstacle pointed out to its
wider use was the too long time for the spirometry to be performed. GPs’ main reason for prescribing a bronchodilator
is dyspnea and bronchodilators preferably prescribed are LABA and LAMA. Control of patient’s adherence to therapy is
mainly carried out by GPs checking the number of drugs annually prescribed or asking the patient during a control visit.
Finally, about how many COPD patients GPs believe are in their group of assisted patients, a mean range of 25-40
patients was reported, that is consistently below the forecast based on epidemiological data and number of
patients assisted by each GP.
Conclusions: The results obtained with this project confirm the validity of this informal approach to professional
education. Furthermore, this inquiry provided important insights about the general management of COPD and the
process of integration between RS and GPs activities on this disease condition in the long run.
Keywords: COPD diagnosis, Early diagnosis, General practice, GPs, Respiratory specialist, SpirometryBackground
Chronic Obstructive Pulmonary Disease (COPD) is a
respiratory pathological condition caused by a chronic
abnormal response to noxious inhaled agents, mainly
cigarette smoking, characterized by persistent and mostly
irreversible airflow limitation determined by bronchial
alterations (chronic bronchitis), small airways disease
and parenchymal destruction (pulmonary emphysema),
and associated with systemic complications and frequently
occurring comorbidities (cardiovascular diseases, cancer,
osteoporosis etc.) [1-3].
Noncommunicable diseases, among which COPD holds
a prominent position, are responsible for more than 35
million deaths worldwide, a conspicuous rate that in-
creased from 57% of total mortality in 1990 to 65% in
2010, and also sets a relevant burden in terms of
disability-adjusted life-years (DALYs) [4-6]. Estimates
of COPD prevalence in Europe are between 5 and 10%
with a wide variation among different countries and in
relation to the employed methodology, while the mortality
rate is about 18 per 100,000 subjects per year [7].
Respiratory diseases are the third cause of death in
Italy and COPD is responsible for about half of respiratory
deaths when lung cancer is excluded [8]. On the basis of
the National Institute of Statistics (ISTAT) data [1], about
5% of adult Italian males are allegedly affected by COPD
and about 4% of women (i.e some 2,600,000 of Italian
citizens). However Viegi et al. found that 9.9% of
people between 25 and 45 years suffer from obstructivedisorders while in the overall age-range of 25-73 years
a percentage spanning from 11% to 40% of people are
affected depending on which criterion is applied among
European Respiratory Society (ERS), clinical criteria, or
American Thoracic Society (ATS) ones [9]. This hypothesis
is supported also by a study in the real world which demon-
strated relevant underdiagnosis and undertreatment [10].
This respiratory disease represents also a heavy charge
in terms of social and economic costs, especially when it
has reached a more advanced severity with increased
incidence of acute exacerbations and hospital admissions.
At this stage, there is an unavoidable need for continuous
use of bronchodilators, inhaled or systemic corticosteroids
and antibiotics, long-term oxygen therapy, rehabilitative
programs, and other treatments related to various co-
morbidities, mandatory to improve and maintain patient’s
health status [11-13].
COPD presents with persistent cough, sputum pro-
duction, dyspnea and decreased exercise tolerance, but
these symptoms are often disregarded by patients, in
the majority smokers, in less severe stages of the disease
because considered as unavoidable consequence of smok-
ing habits instead of evidence of a disease. In fact, several
studies demonstrated that the patient may well experience
symptoms but do not always report them to his General
Practitioner (GP) [14,15]. Thus, in most cases the diagnosis
of COPD is carried out when the disease has already
reached a moderate-to-severe level both of airflow ob-
struction and symptoms [16-18].
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respiratory symptoms in primary care can favour the
early detection of COPD [19] as well as the use of the
cards of respiratory risk [20]. Both these methods can
screen patients and address them to a spirometry in
order to confirm the diagnosis of COPD [21]. Indeed,
spirometry is performed in a low percentage of patients
suspected to have COPD and the diagnosis is often
based on clinical findings only [22]. Recent data from
particularly committed GPs database show a percentage
of COPD diagnosis backed by spirometries of 60% [23].
Office spirometry [24] has been proposed as a mean to
increase the amount and the correctness of COPD diag-
noses and it proven to be feasible by general practitioners
(GPs). However many problems concerning time availabil-
ity, competence to interpret the results, patient’s adher-
ence to test, and other organizational factors have so far
impaired a more widespread use of spirometry, that is an
easy doing test, very important to qualify the diagnosis,
and assess the grade of disease severity together with other
clinical parameters like number of previous exacerbations,
nutrition status, dyspnea score etc. [25]. Likely, a critical
factor to extend the diffusion of spirometry in general
practice would be to increase GPs believe of its utility
for the diagnosis of COPD, as demonstrated in some
studies [26].
Many international guidelines have been published in
the last ten years [3]. Since 2011 there are Italian official
guidelines from the Ministry of Health [1], which have
been updated in 2013 by the three mayor respiratory
scientific societies together with a GP scientific society
[2]. All these documents give recommendations on
how to improve the diagnosis and treatment of COPD
patients and to control the costs of this disease. However,
there are many proofs that guideline recommendations
for management of COPD are not adequately followed in
clinical practice both by GPs [27] and also by some re-
spiratory specialists especially in relation to treatment
[28,29]. In particular, the observed prevalence of COPD in
records of GPs is notably lower than would be expected
according to what found using health questionnaires and
specific studies [30] and this means that a great part of pa-
tients are not diagnosed and consequently not treated.
These missing diagnoses have been measured in Italy in
situation applying the WHO-GARD strategy for diagnosis
(and were shown to reach percentage as high as 70%) [31].
On the other hand, respiratory specialists mainly deal with
severe or very severe COPD, often in hospital, having
scarce possibility to manage less severely affected subjects
who undergo the greater reduction of respiratory function
and represent the more consistent part of COPD patients.
Such a situation clearly points out the need for a close
cooperation between GPs and respiratory specialists to
increase the knowledge of COPD risk factors, its clinicaland functional peculiarities, especially in the initial stages,
the differential characteristics from other respiratory
obstructive diseases like asthma, and the correct man-
agement and follow-up. A better knowledge of the disease
and a wider use of spirometry are critical to diagnose
more patients still neglected, do it at an earlier stage and
properly treat established COPD.
Moreover, once diagnosed, patients suffering from COPD
in most cases (except, in some areas in Italy, people treated
with long term oxygen therapy) do not experience no long
term follow up of the disease and no offer of pulmonary
rehabilitation [28] while they are poor compliant with
the pharmacological treatment [32].
In the light of the above mentioned considerations,
FISAR (the charity of reference of the Italian Interdiscip-
linary Association for Research in Lung Disease - AIMAR,
advocating for respiratory health improvement) devised
and realized a project, called Pneumocafè using an infor-
mal setting of meetings (i.e. non ECM events) between
GPs and their respiratory specialists (RSs) of reference.
The aim of Pneumocafè project is to improve, through
an innovative approach, the diagnosis and management
of COPD at primary care level, increasing the awareness of
issues pertaining to early diagnosis, adequate prevention
and correct treatment of the disease.
Methods
The project was based on a series of informal meetings
to be held all over the Italian territory where a RS, after
pointing out the main characteristics of COPD diagnosis
and management, discussed in a colloquial manner with
the attending GPs their current practice compared with
what official guidelines suggest, analyzed the actual prob-
lems in diagnosing and managing COPD patients, and
shared the possible solutions at the community level for a
more correct approach to these issues.
In the space of 30-45 days 50 RS, selected as to cover
all Italian territory, had to perform a mean of 5 meetings
lasting about 2 hours, each including a group of 10 GPs
working in their reference zone. Thus, at the end of the
arranged period, each RS would have met about 50 GPs.
Time and location of the meetings were scheduled in
agreement with the GPs, generally in hospital clinic or
in GP’s group surgery. In these meetings RSs, also starting
from clinical cases reported by them or by attending GPs,
faced many issues including patho-physiological mech-
anisms of bronchial obstruction, significance of clinical
symptoms, patients’ phenotyping, and clinical approach
to diagnosis and long-term treatment, and gave strength
to messages concerning the importance of a timely diag-
nosis, proper long term treatment and the compliance to
treatment.
RSs were recommended to present practical materials
like representative spirometric graphs, questionnaires, and
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board of the project. These tools represented the basis for
a discussion with the GPs on site and then were given
them to be delivered to patients in each surgery, so as to
spread adequate information on a given territory.
A following phase of implementation of this educational
process is planned, when GPs, made aware of the prob-
lems, will be able to screen suspect cases among their
assisted people sending screened subjects to RSs to have
the diagnosis confirmed.
At the end of each meeting GPs had to fill in a question-
naire arranged by the scientific board that included 18
multiple-choice questions concerning their approach to
COPD management (Additional file 1).
RSs, after the cycle of meetings they held with GPs, were
requested to fill in a quality questionnaire to express their
comment on this new format, suitability of educational
materials, level of GPs participation, possible interest to
repeat similar meetings on the same or other topics of
respiratory medicine.
The results of the analysis of these questionnaires are
here presented; descriptive statistics is used to analyze
the data, reported as percentage to the total, and as
range of variability (min-max) when requested.
Results
1, 964 questionnaires were returned from 49 RSs. 1,864
questionnaires out of those received (94.91% of the total)
resulted properly compiled and form the object of the
present analysis.
The 49 RSs, 37 males and 12 females, were distributed
all over the Italian country and practiced their profession
both in public and private hospitals and in territorial
sanitary facilities.
GPs were 1,330 males (71.35%) and 534 females (28.64%),
mean age 56,29 years (range 27-70 yrs). The provenience of
participating RSs is reported in Additional file 2, while the
number of questionnaires deriving from each center is re-
ported in Additional file 3 and Figure 1.
The geographical provenience of GPs along the Italian
territory and the relative questionnaires are resumed inFigure 1 Number of questionnaires returned by each of 49 RS (horizo
returned questionnaires).Figure 2. There is a marked prevalence of GPs practicing
in north Italy (907 questionnaires), but also the other
zone are well represented. Mean duration of general
practice is 25.56 years (range: 0,5-40 yrs) with a mean of
1,302.43 patients assisted by each GP and 2,427,741 pa-
tients assisted in all.
To know which order of priority GPs give to patho-
logical conditions that prevalently occur in their practice,
and in particular to COPD, also to have an indirect meas-
ure of the prevalence of these disease, they were asked the
question “From an epidemiological point of view which
order of importance (1 =most important, 5 = least import-
ant) do you assign to the following diseases in the popula-
tion of patients you assist?”. More than 60% of GPs
answered that in their patients COPD has a mean-to-great
prevalence (Table 1), preceded in terms of priority (score
1 + 2) only by diabetes and heart failure. Cancer and other
chronic diseases seem less important according to their
epidemiological burden.
In terms of impact COPD has on GPs practice it was
scored as mean/high, similarly to heart failure, while the
priority was again assigned to diabetes (Table 2).
Subsequently, GPs were requested to indicate which
COPD guideline they preferentially adopted in their clin-
ical practice and the majority of them answered they were
using GOLD guidelines (almost 62%), whereas almost a
quarter of GPs affirmed they carried out their practice
without using any guideline (Table 3).
Regarding early diagnosis of COPD and what in general
should be done to improve it, the prevalent opinion of
GPs (1,598 GPs, 85,73%) is that a screening on groups of
patients at risk (active smokers or ex-smokers aged ≥
40 years) might be a useful tool (Table 4).
With reference to GPs’ individual practice, at the
question whether an early diagnosis of COPD would be
possible in the group of patients they assist, 65.4% answered
positively even if some pointed to possible problems raised
by costs or adherence by patients, whereas only 3.1%
affirmed it was impossible (Figure 3).
As to patient’s smoking habits, GPs should have updated









Figure 2 Geographic distribution of GPs and number of
questionnaires received from each area.
Sanguinetti et al. Multidisciplinary Respiratory Medicine 2014, 9:35 Page 5 of 14
http://www.mrmjournal.com/content/9/1/35GPs declared to be able to always know how many
smokers or ex-smokers are in their group of patients,
whereas almost half of them were not informed on
smoking habits of their assisted. GPs behave differently
when dealing with a smoker and a personal care to help
them to give up smoking is displayed only by about 30%
of them (Table 5).
GPs were also asked to express their opinion on what
would be the cigarette amount exposing patients to the
greatest risk for COPD and the majority (58.37%) an-
swered 30 py (pack years = number of daily cigarette
packs by number of smoked years), while 18.72% re-
ported 20 py, 11.96% 10 py, and 10.95% affirmed they
did not know.
With the aim of investigating the GPs knowledge about
COPD exacerbations, another question was formulated
regarding the GPs opinion about the statement that the
majority of acute bronchitis episodes occurring in general
practice are exacerbations of COPD, and this was agreed
by 1,623 participants (87.07%).
Coming to the diagnosis of COPD, the majority of
GPs recognize spirometry as necessary to diagnose the
disease, while one third of them think it is necessary but
not sufficient to reach the diagnosis and a very little per-
centage believe that COPD diagnosis must be based on
clinical elements (Table 6).
In relation to spirometry availability to enhance the
diagnosis of COPD in general practice, GPs mainly an-
swered that having this facility in the health district of
their reference would be the best solution, although a
not negligible percentage of them affirmed the utility of
a spirometer in their surgery (Table 7).Table 1 Epidemiological importance of COPD and other chron
Score* Heart failure Diabetes COPD
1 463 840 128
2 468 517 583
3 426 280 763
4 387 207 344
5 120 20 46
Total 1,864 1,864 1,864
*1 =most important, 5 = least important.Moreover, GPs have been asked what in their working
place was the main obstacle to early COPD diagnosis and
the main impediment pointed out in all districts of GPs
provenience was the too long time to be waited for the
spirometry to be performed (55.74%), followed by the cost
patients have to sustain for this examination (17.97%)
(Table 8).
As to the GPs ability to manage specific clinical cases,
they were requested to choose among different possibilities
inherent the diagnostic work-up of a patient 50 years old
suspected of having COPD and presenting normal results
of a simple (only forced expiratory volumes) spirometric
examination. The majority of GPs (40.95%) revealed they
would send such a patient to the respiratory specialist,
while 28.75% would make patient to perform a global spir-
ometry possibly also with a bronchodilation test (Table 9).
In another clinical case, GPs were asked which is the
first test they would perform in an old ex-smoker patient
claiming of exertional dyspnea and the prevalent choice
was a spirometric examination (sum of simple and global
spirometry percentages), followed by ECG, cardiologist or
pneumologist consultation (Table 10).
Concerning the therapeutic approach to COPD, GPs’
main reason for prescribing a bronchodilator is dyspnea,
followed by cough and sputum production, whereas the
least importance is attributed to the patient’s capacity of
performing daily activities (Table 11).
Bronchodilator drug GPs preferentially prescribe to a
symptomatic patient with mild-to-moderate COPD at
first diagnosis is a long-acting beta-2 agonist taken on a
regular basis, and the second preferred choice is a
long-acting antimuscarinic drug (i.e LABA or LAMA
are prescribed by more than 60% of GPs) (Figure 4).
GPs were also asked whether and how they verify the
adherence of their patients to the arranged therapeutic
plan and the correct uptake of drugs. The majority of
GPs (47.41%) answered they ask patients information
about their adherence to therapy during a control visit,
whereas another consistent percentage of GPs affirm they
check in their records the number of drugs prescribed
annually and only 10.41% of them let patients verify on
their own the adherence to therapy (Figure 5).ic diseases based on GPs clinical practice







Table 2 Answers of GPs to the question “How do you score these diseases in terms of impact on your practice?”
Score* Heart failure Diabetes COPD Cancer Other chronic diseases Total
1 458 727 159 421 99 1,864
2 498 509 545 249 63 1,864
3 414 379 699 284 88 1,864
4 385 224 388 698 169 1,864
5 109 25 73 212 1,445 1,864
Total 1,864 1,864 1,864 1,864 1,864
*1 =most important, 5 = least important.
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they estimated to be in the whole group of patients they
assisted (Table 12 and Figure 6), and a wide variability of
prevalence was reported, the most frequent numbers in
the whole group of GPs being 20 to 30 and 30 to 40
patients. However, in southern Italy there was a consistent
number of GPs reporting they have more than 50 COPD
patients. On the average the estimated number of COPD
patients declared by GPs is consistently below the forecast
in accordance with the epidemiological data and the num-
ber of patients assisted by each GP.
The agreement of RSs towards such type of meetings
has been recorded in a questionnaire, whose results are
summarized in Tables 13 and 14.
Discussion
COPD is a frequently encountered chronic disease condi-
tion in primary care, however the official prevalence data
underestimate the real burden of the disease that often is
recognized only when has already reached an advanced
stage [14,16], such as in a not negligible number of patients
in the community the disease is not diagnosed and effective
treatment not delivered or delayed.
Besides unrecognizing symptoms suggestive for COPD,
spirometry is underutilized in general practice [33,34],
and in Italy at least 30% GPs do not use spirometry to
diagnose COPD because they consider this examin-
ation not necessary or claim of logistical limitations
[35].Table 3 COPD guidelines GPs preferentially use in their
clinical practice
Type of Guideline N %
GOLD guidelines 1,150 61.70
Guidelines of Italian Agency for Health
Services (AGE.NA.S)
69 3.70
Guidelines of the Italian Respiratory
and General Medicine Associations
230 12.34
No guidelines, following recommendations
of pulmonary specialist
415 22.26
Total 1,864 100Therefore a better approach to COPD diagnosis and
management in general practice appears mandatory to
decrease the rate of underdiagnosis and undertreatment,
and in this context is crucial the cooperation between
RSs and GPs.
The unusual format of professional education devised
in Pneumocafè Project, as results from the RSs’ answers
to quality questionnaire, has been agreed by the wide
majority of them, who believe this event is also an op-
portunity to know other GPs or reinforce the relation-
ships with those already known, also receiving from
them new patients to study because suspected of having
respiratory diseases. Furthermore, this colloquial format
without slides has been recognized by RSs as an effica-
cious tool to transfer scientific information to GPs, who
endorse it much more than in a classic congress. The
quality of educational material has been mostly believed
as suitable for the purposes of the event, however some
RSs would also have multimedial materials to reach a
greater interactivity with the participants, while other
RSs suggest a preliminary collection of GP’s needs (topics,
case reports and other) such as to set the meeting on a
higher level of interactivity.
One of the most distinctive and valuable characteristic
of the present inquiry is represented by the high number
of GPs (assisting more than 2 millions of patients in all)
attending the meetings, whose wide distribution across
the Italian territory gives particular truthfulness and
reliability to the results. In fact, although this project
was not designed to assess the epidemiological prevalence
of COPD using field interviews or other instruments, it
nevertheless allows to draw a comprehensive view of whatTable 4 Proposals of GPs to reach early diagnosis of COPD
Proposal N %
Screening on general population over
40 years of age
266 14,27
Screening on groups of patients at risk
among those they assist (ex- smokers or









Possible but not accepted by
patients
Figure 3 GPs’ opinion about an early COPD diagnosis among
patients they assist.
Table 6 Answers of GPs to the question “How do you
consider spirometry for the diagnosis of COPD?”
Answer N %
Necessary 1,133 60.78
Necessary but not sufficient 683 36.64
COPD diagnosis is only clinical 48 2.58
Total 1,864 100
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ment, valuable to plan future initiatives aimed at improv-
ing the present situation. The greater number of GPs
from Northern Italy in this study is accounted for by the
larger population and consequently the greater presence
of GPs and RSs in this area of the Country.
According to the belief of GPs participating this investi-
gation, the epidemiological burden attributable to COPD
in their experience is not negligible, lower than diabetes
but equal to chronic heart disease. In this regard, several
studies demonstrated that COPD patients are at increased
risk of cardiovascular morbidity and mortality [36,37] and
the cardiovascular comorbidity can often represent a pri-
ority in the management of the patient. On the other
hand, among patients admitted to hospital for chronic
heart failure the presence of COPD has been found in
about 35%, but only 43% of them reported to have COPD,
whose one-third had the diagnosis of COPD confirmed by
spirometry [38,39]. As to concerns the impact on their
practice that GPs attribute to diabetes, the prevalence of
this disease in Italy has recently estimated to be 4.9% [40],
apparently not different from that of COPD. However, the
diagnostic approach to diabetes is easier and based on
simple parameters like blood glycemia or glicated haemo-
globin, thus the estimated prevalence of this disease likely
approximates reality more than that of COPD. In addition,
specialized clinics for diabetes supporting general practice
are much more numerous and more organized than
respiratory services in Italy.
In the present inquiry GOLD guidelines [3] are re-
ported to be referred at by over 60% of GPs. GOLD hasTable 5 Actions carried out by GPs to help a patient to
give up smoking
Actions N %
I help him to give up smoking with a minimal
advice (five “A”)
606 32.51
I address him to a specialized center for smoking
cessation
479 25.70
I would address him to a specialized center for
smoking cessation should there be any available
306 16.42
I only say him that he has to give up smoking 473 25.37
Total 1,864 100been formed in 1998: since then various updated editions
of this initiative followed and also Italian translations
have been published in recent years. National institu-
tional documents [1,2] drawn to adequate and uniform
the approach to COPD by Italian physicians have been
published more recently, especially the last one [2]. Due
to recent diffusion of these documents, it is probable
that GPs are not completely aware of this availability
yet. Besides, if one GP already got used consulting a
given guideline, moreover the only available to him for a
long time and with which he gained some familiarity, it
is possible that he can have some difficulties to change
his reference. Use of guidelines to increase COPD diag-
noses is still widely discussed, even if recent investigations
report that the more updated guidelines can identify
greater proportions of patients in the mildest and most
severe categories, however without avoiding discordances
between airflow limitation severity and exacerbation risk
[41]. Instead, it seems difficult to find the reasons why
over 20% of GPs do not consult any guideline but only
refer to RS. This could be they do not know the guide-
lines, or better they have good and easy relationships with
the reference RS. Alternatively, they might be not
confident at all in guidelines, or do not want to engage
themselves in a consultation that is time-consuming
and does not always help to work out specific problems
but only give general recommendations to be applied
in each clinical context. However, it is a general obser-
vation that, in spite of progressive improvement of
evidence-based guidelines production and dissemination,
their awareness is not sufficient and their use for day-
to-day care is still scarce [42], also because guidelines
are generally developed by experts who pay more atten-
tion to methodological rules and quality grades than to
the objective of integrating scientific evidences into prac-
tice [43]. The inclusion of GPs in drawing up guidelines isTable 7 GPs’ opinion about spirometer availability to
favour the diagnosis of COPD
Opinion N %
Spirometer in own surgery 717 38.46
Spirometer in health district of reference 825 44.26
More spirometers in hospital 322 17.28
Total 1,864 100
Table 8 Main obstacles to early COPD diagnosis GPs encounter in their working places
Obstacles N % North Center South Islands
Spirometry availability too far 271 14.54 122 41 80 28
Cost of the examination 335 17.97 159 41 98 37
Too long time to be waited for spirometry 1,039 55.74 523 247 208 61
Lack of respiratory specialists in that district 219 11.75 103 58 47 11
Total 1,864 100
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in “real-life” and this is the reason why the recent national
document on COPD diagnosis and management [2]
has provided the participation of a GP’s scientific soci-
ety under the control of Italian Ministry of Health. In
addition, it is not sufficient to disseminate the guide-
lines on a national basis to reach an acceptable level of
application, but they should be also implemented at re-
gional and local level. In this respect, some projects
have been devised to implement the knowledge of
guidelines among GPs, based on multifaced knowledge
translation interventions consisting of interactive educa-
tion, quality circles and practice-based tools in primary
care [44]. Some projects consider useful to increase dis-
semination of guidelines, like the “Knowledge to Action”
(KA) [45] that recommends using tailored and compre-
hensive approaches at different level (doctor, team prac-
tice, hospital etc.) after assessing local barriers, available
resources and other practical aspects, and in some coun-
tries institutions adopting specific KA processes have been
charged with the implementation of respiratory guidelines
[46]. However, a critical review of the results of theories so
far adopted in many studies for this purpose points out
they are not satisfying and the approach needs further
improvement [47,48]. In our country this task is mainly
carried out by respiratory scientific associations and
Pneumocafè project was just designed to comply with
this need.
Early detection of COPD, so as of other respiratory
diseases like lung cancer, is a significant issue [49] as it
would increase finding patients affected by the disease
and also favour the possibility of undertaking efficaciousTable 9 What GPs would choose to do in a 50 yrs old
patient suspected of COPD and presenting normal results
with a simple spirometric test
Choice N %
Investigating an alternative diagnosis 175 9.40
Request a global spirometry 390 20,90
Request a global spirometry with bronchodilation test 536 28,75
Request consultation of a respiratory specialist 763 40,95
Total 1,864 100preventive and therapeutical measures, thus improving the
long-term prognosis of these patients [15,50]. However, this
represent a worldwide problem [51], since at the beginning
of the present century 10 million physician-diagnosed
COPD diagnoses have been reported in U.S.A., that is
much less than what expected based on the 24 million
adults with impaired lung function according to NANHES
III survey [52]. Similarly, in a Dutch Survey [53] the preva-
lence of self-reported COPD was almost twice as high as
the prevalence based on GP registration. This has also
heavy economic implications because the cost of advanced
and severe forms of COPD is as much as seven times
higher than that of mild cases [54,55].
Obviously, COPD underdiagnosis and undertreatment
mainly relate to the mild stages of the disease and the
causes may be various. Some authors [14] recognize as a
crucial factor the need for more evidence of beneficial
effects of interventions on patients with mild symptoms,
because if this is true the approach can become cost-
effective. More likely, the reasons for underdiagnosis should
be attributed both to the patients and to the physicians,
because 33% of patients at high risk of COPD and present-
ing symptoms never consulted their physician. On the
other hand, among COPD patients who consulted the
physician only 60% performed spirometry [55]. Thus, a
better knowledge of COPD symptoms must be enhanced
not only among GPs, but also in general population, as
well as a more widespread use of spirometry as a tool to
functionally qualify clinical symptoms and/or to reveal
possible functional alterations in subjects not presenting





Cardiologist consultation 408 21.90
Pneumologist consultation 391 20.97
Simple spirometry 348 18.67
Global spirometry 228 12.23
Total 1,864 100
Table 11 Reasons why GPs prescribe a bronchodilator drug
Score* Dyspnea Level of bronchial obstruction
at spirometry
Cough Sputum production Capacity of performing
daily activities
Total
1 752 713 54 20 325 1,864
2 790 509 176 117 272 1,864
3 168 317 812 178 389 1,864
4 34 214 641 829 146 1,864
5 120 111 181 720 732 1,864
Total 1864 1864 1,864 1,864 1,864
*1 =most important, 5 = least important.
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in routine care to make an early diagnosis of COPD in pa-
tients with lower respiratory tract symptoms and several
long-term comorbidities.
In this inquiry the great majority of participating GPs
confirmed the importance of early COPD diagnosis and
they think the best method to accomplish this purpose
would be to perform a screening among their assisted
patients who are at risk for this disease, namely smokers
or ex smokers aged 40 years or more. The majority of
GPs think that this task is feasible in their clinical prac-
tice, although at least 30% of them raise some difficulties
relative to the costs and the patient’s acceptance of such
screening.
As for where the spirometry could be delivered, the
majority of GPs point to the health district of reference
while a percentage as high as 38% think own surgery as
the best setting.
However, a previous Italian study on symptomatic pa-
tients only showed that spirometry, while certainly feasible
in the general medicine setting, encounters poor enthusi-











A long acting beta2-




A fixed combination beta
agonist long-acting /
inhaled corticosteroid
I ask for advice and I rely
on the advice of the
specialist Pulmonologist
A combination beta2
agonist and short acting
antimuscarinic
Figure 4 Bronchodilator drugs preferentially prescribed by GPs to
a mild-to-moderate symptomatic COPD patient at first diagnosis.non-negligible problems regarding the maintenance of ad-
equate standards of performance and interpretation [24].
A valid support to improve early diagnosis of COPD
might be the use of questionnaires especially in practice-
managed conditions [19,21], while other experiences
[59,60] point out the validity of making an early diagnosis
of COPD through smoking cessation programs.
The common remark that spirometry is performed
much less frequently than what would be necessary
[22,35,51,55] could be related to the fact that GPs do
not believe necessary this examination and base their
diagnosis only on clinical issues. Indeed, this does not
seem the true or the main reason because in the
present survey it emerged that almost two thirds of
GPs believe spirometry necessary to diagnose COPD
and only less than 3% think COPD diagnosis is only
clinical. Thus, it is conceivable that spirometry is not
sufficiently available in general practice at present and
should be further provided both in terms of number of
facilities that can perform it with an easy access, and in
terms of greater familiarity with this examination, ability
to interpret the results, and availability to perform it in
one’s own office. In fact, in this inquiry GPs expressed
with the same percentage the wish to have more spirome-
ters in the health district of their reference or a spirometer
in their surgery. The main reason GPs point out for the
lack of spirometric examinations is the too long time
awaited for the spirometry to be performed. However,
there is still a general belief in general practice that10.41
42.49
47.1
I leave to the patient
monitoring adherence to
therapy
I check in my personal
archive the number of
pieces / year prescribed
I ask the patient about
adherence to therapy
during a visit to an
exacerbation of COPD
Figure 5 How GPs assess patient’s adherence to therapy.
Table 12 Number of COPD patients GPs estimate to be
present in their group of assisted patients
N of patients N of GPs % North Center South Islands
0 to 10 124 6,65 63 18 28 15
11 to 20 339 18,19 176 54 81 28
20 to 30 446 23,93 253 94 75 24
30 to 40 400 21,46 199 93 80 28
40 to 50 266 14,27 118 55 71 22
More than 50 289 15,50 98 73 98 20
Total 1,831 100
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http://www.mrmjournal.com/content/9/1/35implementation of spirometry is complicated [35,56]
and that training of GPs for interpreting spirometry is only
a part of the solution [57], so as the better intervention
would be to increase spirometry services [34].
All these considerations urge to better arrange the re-
spiratory health framework all along the Italian territory,
by incentivizing the possibility of performing spirometry
and the relationships between GP and RS for a continu-
ity of care to patients affected with COPD. This emerged
also from the behaviour of general practitioners about
the clinical cases they have been asked to manage in this
inquiry, where the consultation of a respiratory specialist
has been the measure mostly requested.
The tobacco epidemic has now become a global
phenomenon, and it represents a problem also in our
country, where smoking has a prevalence of 26.2%
among adults (30.0% in males and 22.2% in females)
[61] and smoking related diseases are responsible for
10% of deaths of adult population. Active smoking un-
deniably is the main avoidable cause of morbidity and
mortality, and the main risk factor for COPD, lung
cancer and cardiovascular diseases. Thus, it is very im-
portant to realize that effective interventions to help
smokers cease their habitude and to convince non-
smokers not to start smoking. Furthermore, tobacco
smoking is not only the main cause of many respiratory
disease conditions, but also a cause of worsening of an
established respiratory disease. On the contrary, quitting












Figure 6 Number of COPD patients GPs estimate to be present
in their group of assisted patients.more severe levels of disease and invalidity. For these rea-
sons chest physicians have been invited to consider smok-
ing cessation as an essential therapeutic measure, the first
provision to give the active smoker at the very moment of
the first diagnosis of COPD [1,62]. A person whom a
smoking related disease has been diagnosed and who still
is an active smoker should be considered a “hard-core
smoker” [63]. These kind of smokers should be treated
with an “intensive treatment”, far more intensive than the
so-called “minimal advice” (or 5As method) [64], which
can be delivered only by specifically trained staff in a
specialized setting. In our survey, only one out of four
GPs refers such patients to the proper treatment (a
specialized centre for smoking cessation); the remainders
(i.e. the majority) are divided into: one other quarter
which does almost nothing (only “recommending” to
quit), one third which delivers a minimal advice and
another 16% which would refer the patient to a smoking
cessation clinic, were this latter available. It then comes
that only a minority of COPD smokers can actually re-
ceive the proper treatment they deserve.
COPD is characterized by persistent airflow limitation
and lung hyperinflation both in static and dynamic
conditions, and the main symptom patients claim about is
exertional dyspnea, that in the most severe cases can also
make impossible the normal daily activities. Therefore,
bronchodilators, especially the long-acting ones, both beta-
adrenergic and antimuscarinic [65-68], are the cornerstone
of the long-term treatment of this disease, because they
decrease the airways resistances and lung hyperinflation
and improve symptoms, exercise tolerance and reduce the
rate of acute exacerbations also improving patient’s daily
life and slowing up the disease progress. It has been dem-
onstrated [69,70] that early morning is the worse period
of the day for COPD patients, thus an inhaled broncho-
dilator capable of inducing a rapid bronchodilation and
maintaining it for 24 hours, is a real advantage for these
patients and increases their adherence to therapy. A sig-
nificant correlation has been demonstrated after broncho-
dilator use between the decrease in inspiratory capacity
and the reduction of dyspnea level [71]. Moreover, it is im-
portant that the inhaler be user-friendly and characterized
by a low internal resistance so as to be effectively used also
with low inspiratory flows. In conformity with these
pathophysiological and clinical issues, in this inquiry the
leading reason for GPs prescription of bronchodilators in
their COPD patients is just because they complain about
dyspnea and present a marked grade of airflow limitation
at spirometry, and the long-acting bronchodilators are
mainly prescribed (more than 60% of GPs).This is in
accordance with the evidence-based guidelines that rec-
ommend the use either of a LABA or of a LAMA as first
choice for the long-term treatment of COPD, while the
two bronchodilators can be used together if necessary. In
Table 13 Results of the agreement questionnaire filled in by RSs (results are expressed as percentage on the whole
group of RSs)
Issue Excellent Good Sufficient Insufficient
Relevance of treated topics for educational purposes 66.0 34.0
Level of participation/interest of GPs 41.5 55.0 3.5
Quality of educational material 83.0 14.0 3.0
Impact of the event on RS’s daily practice 34.5 55.0 10.5
Evaluation of this novel format 48.0 38.0 10.5 3.5
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on bronchial tone may be in some patients more suitable
than adding corticosteroids to decrease the lung hyperin-
flation and increase exercise tolerance, and in this context
various combination of different bronchodilators are now
ready to be introduced in clinical practice [72].
A non negligible percentage of GPs (about 12%) pre-
scribe only short-acting bronchodilators (SABA) as
needed to COPD patients. This can be interpreted that
the majority of their patients have a mild disease, although
a beneficial effect has been demonstrated in COPD with a
long-term treatment beginning in the first phases of the
disease, where therapy can prevent the functional decline,
much more marked at this stage, and significantly modify
the outcome [73,74]. The GPs who prescribe only SABA
in COPD seem to have insufficient knowledge of patho-
physiological aspects of the disease or alternatively mainly
look at the costs of therapy that are lower with SABA than
with Long-acting bronchodilators, although SABA should
be used only during acute exacerbations as rescue therapy,
as extensively recommended in COPD guidelines [1-3].
More than 14% of GPs affirm to prescribe a fixed combin-
ation of LABA and ICS (inhaled corticosteroids). Such an
approach does not seem to comply completely with the
recommendations of guidelines (GOLD included) accord-
ing to which this choice should be kept for most severe
patients showing a high annual incidence of exacerbations
or for COPD patients with an asthmatic comorbidity. We
have no data on how many Italian COPD patients could
be included in these two sub-populations, and the type
and severity of COPD patients have been demonstrated to
vary in different clinical series, even if an exacerbator
phenotype has been identified among COPD patients [75].Table 14 Opinions of RSs about repeatability of events
with this format (results are expressed as percentage on
the whole group of RSs)
Question Yes No Don’t know
Do you think GPs are interested in
participating in other similar events
on different respiratory topics?
93.0 7.0
Are you interested in participating in
another educational event like
Pneumocafè?
93.0 7.0Therefore, we can draw no conclusion about the appro-
priateness of this prescription, and generally speaking a
certain over prescription of LABA/ICS combination can
be supposed.
It is axiomatic that a certain therapy results beneficial
to patients provided that they take the drugs and do it
correctly, that is they are adherent to treatment, and the
practice of complying with a medication regimen must
be considered as important as the effect yielded by the
medication [76]. In fact, a lower adherence to treatment
can cause marked worsening of health status [77],
whereas the adherence to inhalation therapy in COPD
is associated with a lower risk of death and hospitalization
for COPD exacerbations [78]. The adherence to treat-
ment in COPD takes advantage of a simplification of
therapeutical regimen by reducing the number of doses,
and of the prescription of user-friendly inhalers and rap-
idly acting drugs whose effect can be perceived by the
patient [79,80].
Adherence to therapy, however, cannot be assessed
only at the beginning of treatment, but must be checked
periodically to have the certainty that the patient takes
the drugs and does it correctly, but the ways to do this
are not codified and often let to the individual initiatives.
In this respect, the majority of GPs in the present
inquiry affirm they ask patients information about their
adherence to therapy during a control visit, whereas a
little lower percentage of GPs declare to check in their
records the number of drugs they prescribed to the
patient during the year. These control initiatives does
not assure that patients really took the drugs in a given
period of time, even if the clinical course of the disease
in the same period can be an indirect indicator of
whether the drug has been taken or not. In a survey on
more than 25 thousands COPD patients, those who were
taking combination LABA/ICS (inhaled corticosteroids)
had better adherence than those taking jointly the single
drugs and adherence was better for a once daily (OD)
agent than a multiple-dose-per-day agent while it was
less associated with patient’s level or comorbidities than
with drug delivery factors [81].
The last question GPs were asked to answer in this
inquiry was inherent to the number of COPD patients
they estimated to be among the own group of assisted
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not been possible to establish with certainty a mean
number of COPD patients, however the ranges be-
tween 20 to 30 and 30 to 40 patients have been chosen
by the higher number of GPs without clear differences
according to geographic residence. Thus it seems likely
that 30 is more or less the number that the majority of
GPs believe representing the COPD amount among
their group of assisted patients. These data are a con-
firmation of COPD underdiagnosis, because according
to a mean number of 1,300 assisted patients per GP and a
5% prevalence of COPD in adult population, each GP
should count on the average 50-75 COPD patients among
their assisted.
Conclusions
This Pneumocafe’ project was aimed at providing data
about COPD management in a general practice as well
as at testing a new and more informal approach to pro-
fessional education and our results, in our opinion, con-
firm the validity of this approach. This non academic
opportunity seems very suitable to understand and solve
some doubts and possibly to remove obstacles not allowing
a correct management. Besides, the present study provided
important insights about the general management of
COPD as a chronic disease condition and about the
process of integration between RS and GPs activities
on this condition in the long run.
A general conviction has emerged that the awareness
about COPD, especially when it is at an early stage, should
be increased, not only among GPs but also in general
population. For this purpose the active participation of
GPs in these meetings can warrant a wider spread of
COPD knowledge among the general population which
should pay more attention to the often neglected symp-
toms of the disease, the damages it can determine if not
treated and the ways to avoid them.
Finally, an improvement of knowledge of the character-
istics and activities of the management of COPD appears
to be necessary after our results.
Even if spirometry is recognized to have a fundamental
role for getting an early diagnosis of COPD (consequently
allowing interventions aimed at preventing its worsening)
our results showed that this examination is not sufficiently
available or carried out. Most GPs recognize that it should
be diffused to a greater extent and this requirement ap-
pears as a compelling commitment not only for the
physicians themselves but also for the institutional health
officers, responsible for a more efficacious organization of
this field.
Also elements necessary for the management of the
disease, like smoking cessation and pharmacologic treat-
ment after diagnosis seem to need to be refreshed, pos-
sibly through a dissemination of Italian Guidelines.This survey will be repeated in a couple of years after
interventions to measure the change.Additional files
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